A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab in Adult Participants with Moderate to Severe Hidradenitis Suppurativa

ClinicalTrials.gov processed this data on November 1, 2024. Link to the current ClinicalTrials.gov record.

Recruitment Status

RECRUITING (See Contacts and Locations)
Verified November 2024 by MoonLake Immunotherapeutics AG

Sponsor

MoonLake Immunotherapeutics AG

Information Provided by (Responsible Party)

MoonLake Immunotherapeutics AG

Clinicaltrials.gov Identifier

NCT06411899
Other Study ID Numbers: M1095-HS-301
First Submitted: May 8, 2024
First Posted: May 13, 2024
Last Update Posted: November 4, 2024
Last Verified: November 2024
History of Changes

Listing a study on this site does not mean it has been evaluated by the U.S. Federal Government. The safety and scientific validity of a study listed on ClinicalTrials.gov is the responsibility of the study sponsor and investigators. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.

ClinicalTrials.gov, a resource provided by the U.S. National Library of Medicine (NLM), is a registry and results information database of clinical research studies sponsored or funded by a broad range of public and private organizations around the world. Not all studies listed on ClinicalTrials.gov are funded by the National Institutes of Health (NIH) or other agencies of the U.S. Federal Government. Not all listed studies are regulated and/or reviewed by the U.S. Food and Drug Administration or other governmental entities.

Information on ClinicalTrials.gov is provided by study sponsors and investigators, and they are responsible for ensuring that the studies follow all applicable laws and regulations. NLM staff do not verify the scientific validity or relevance of the submitted information beyond a limited quality control review for apparent errors, deficiencies, or inconsistencies.

Choosing to participate in a study is an important personal decision. Before you participate in a study, discuss all options with your health care provider and other trusted advisors. For more information about participating in clinical studies, see Learn About Clinical Studies, which includes questions that you might want to ask before deciding to participate in a study.

For more information about using the information on ClinicalTrials.gov, please also see Terms and Conditions.

See also the Web Policies and Notices for the NIH web site.

Study Description

Not Provided
Condition or Disease Intervention/Treatment
  • Hidradenitis Suppurativa
  • Drug: Sonelokimab
  • Drug: Placebo

Study Design

Study TypeInterventional
Anticipated Enrollment400 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingDouble
Primary PurposeTreatment
Official TitleA Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab in Adult Participants with Moderate to Severe Hidradenitis Suppurativa
Study Start DateMay 15, 2024
Anticipated Primary Completion DateJune 17, 2025
Anticipated Study Completion DateJune 17, 2026

Groups and Cohorts

Group/ CohortIntervention/ Treatment
  • sonelokimab
    • Subjects randomized to this arm will receive sonelokimab 120 mg Q2W from Weeks 0 to 6 then 120 mg Q4W starting at Week 8 up to Week 48.
  • Drug: Sonelokimab
    • Sonelokimab
  • Placebo
    • Subjects randomized to this arm will receive placebo Q2W from Weeks 0 to 6 then Q4W starting at Week 8 up to Week 16. They will receive sonelokimab 120 mg Q2W for 4 doses from Weeks 16 to 22 then Q4W from Week 24 up to Week 48
  • Drug: Placebo

    Outcome Measures

    Primary Outcome Measures

    1. Hidradenitis Suppurativa Clinical Response 75 [Week 16]
      Percentage of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) where HiSCR75 is defined as at least a 75% reduction from baseline in abscess and inflammatory nodule (AN) count, with no increase from baseline in abscess or draining fistula count.

    Secondary Outcome Measures

    1. Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) [Week 16]
      Percentage of participants achieving HiSCR50
    2. Change in International Hidradenitis Suppurativa Severity Score System [Week 16]
      Absolute change from baseline in International Hidradenitis Suppurativa Severity Score System (IHS4)

      The IHS4 score is calculated as follows: number of nodules (multiplied by 1) + number of abscesses (multiplied by 2) + number of draining tunnels (multiplied by 4). A total score of 3 or less signifies mild, 4 to 10 signifies moderate, and 11 or higher signifies severe disease.
    3. Dermatology Life Quality Index (DLQI) [Week 16]
      Percentage of participants achieving a DLQI total reduction of ≥4 minimal clinically important difference among participants with a baseline DLQI ≥4. DLQI produces a numeric score that can range from 0 to 30. A higher score indicates greater health related quality of life impairment.
    4. Reduction from Numerical Rating Scale (NRS30 & NR550) in Patient's Global Assessment of Skin Pain (PGA Skin Pain) [Week 16]
      Percentage of participants achieving at least ≥30% (and ≥50%) reduction and at least 2-unit reduction from Baseline in Numerical Rating Scale (NRS30 & NRS50) in Patient's Global Assessment of Skin Pain (PGA Skin Pain) among subjects with Baseline NRS ≥3
    5. Patient Global Impression-Severity of Illness-Hidradenitis Suppurativa at Week 16 [Week 16]
      Percentage of participants with minimal or absent symptoms using the Patient Global Impression - Severity of Illness - Hidradenitis Suppurativa at Week 16. Participants choose the response that best describes the severity of their disease. The question is rated on a 7-point scale ranging from 0 to 6 (0=absent; 1=minimal; 2=mild; 3=moderate; 4=moderately severe; 5=severe; 6=very severe).
    6. Resolution of draining tunnels (DT100) [Week 16 and Week 52]
      Percentage of participants with zero draining tunnels in the subgroup of participants with at least one draining tunnel at baseline (DT100)

    Eligibility Criteria

    Ages Eligible for Study 18 Years and Older (Adult, Older Adult)
    Sexes Eligible for Study All
    Accepts Healthy Volunteers No
    Inclusion Criteria
    • Participants must be at least 18 years of age at the time of signing the informed consent.
    • Participants who are diagnosed with hidradenitis suppurativa as determined by the investigator and have a history of signs and symptoms of hidradenitis suppurativa for at least 6 months before signing the informed consent.
    • Participants who have had an inadequate response to appropriate systemic antibiotics for treatment of hidradenitis suppurativa (or demonstrated intolerance to, or had a contraindication to, systemic antibiotics for treatment of their HS), in the investigator's opinion.
    • Participants who have a total AN count of ≥5.
    • Participants who have HS lesions present in ≥2 distinct anatomical areas, at least one of which must contain single or multiple fistulas (ie, be Hurley Stage II or III).
    Exclusion Criteria
    • Participants with a known hypersensitivity to sonelokimab or any of its excipients.
    • Participants with any other active skin disease or condition that may, in the opinion of the investigator, interfere with the assessment of HS.
    • Participants with underlying conditions that, in the opinion of the investigator, potentially places the participant at unacceptable risk.
    • Participants with current severe or uncontrolled disease(s) that put(s) the participant at increased risk in the investigator's opinion, would preclude the participant from adhering to the protocol or completing the study per protocol.
    • Participants with any other known autoimmune disease or any medical condition that in the opinion of the investigator would interfere with an accurate assessment of clinical symptoms of HS.
    • Participants with a gastrointestinal condition including inflammatory bowel disease or diagnosis of ulcerative colitis or Crohn's disease.

    Contacts and Locations

    Sponsors and Collaborators MoonLake Immunotherapeutics AG
    Locations
    • Clinical Site | Northridge, California, United States, 91325
    • Clinical Site | Sacramento, California, United States, 95815
    • Clinical Site | San Diego, California, United States, 92123
    • Clinical Site | Coral Gables, Florida, United States, 33134
    • Clinical Site | Hollywood, Florida, United States, 33201
    • Clinical Site | Margate, Florida, United States, 33063
    • Clinical Site | Miami, Florida, United States, 33161
    • Clinical Site | Tampa, Florida, United States, 33607
    • Clinical Site | Macon, Georgia, United States, 31217
    • Clinical Site | Sandy Springs, Georgia, United States, 30328
    • Clinical Site | Columbus, Indiana, United States, 47201
    • Clinical Site | New Albany, Indiana, United States, 47150
    • Clinical Site | Louisville, Kentucky, United States, 40241
    • Clinical Site | Metairie, Louisiana, United States, 70006
    • Clinical Site | Warren, Michigan, United States, 48088
    • Clinical Site | Las Vegas, Nevada, United States, 89119
    • Clinical Site | Portsmouth, New Hampshire, United States, 03801
    • Clinical Site | New York, New York, United States, 10012
    • Clinical Site | Boardman, Ohio, United States, 44512
    • Clinical Site | Dayton, Ohio, United States, 45324
    • Clinical Site | Mayfield Heights, Ohio, United States, 44124
    • Clinical Site | Nashville, Tennessee, United States, 37215
    • Clinical Site | Frisco, Texas, United States, 75034
    • Clinical Site | Houston, Texas, United States, 77004
    • Clinical Site | South Jordan, Utah, United States, 84095
    • Clinical Site | Lynchburg, Virginia, United States, 24501
    • Clinical Site | Mill Creek, Washington, United States, 98012
    • Clinical Site | Winnipeg, Manitoba, Canada, R3M 3Z4
    • Clinical Site | Fredericton, New Brunswick, Canada, E3B 1G9
    • Clinical Site | Barrie, Ontario, Canada, L4M 7G1
    • Clinical Site | London, Ontario, Canada, N6H 5L5
    • Clinical Site | Markham, Ontario, Canada, L3P 1X3
    • Clinical Site | Newmarket, Ontario, Canada, L3Y 5G8
    • Clinical Site | Toronto, Ontario, Canada, M2N 3A6
    • Clinical Site | Toronto, Ontario, Canada, M5A3R6
    • Clinical Site | Quebec City, Quebec, Canada, G1W 4R4
    • Clinical Site | Sherbrooke, Quebec, Canada, J1G 1X9
    • Clinical Site | Białystok, Poland, 15-453
    • Clinical Site | Kraków, Poland, 30-002
    • Clinical Site | Warsaw, Poland, 00-710
    • Clinical Site | Warszawa, Poland, 02-692
    • Clinical Site | Wrocław, Poland, 51-503
    • Clinical Site | Łódź, Poland, 90-265
    • Clinical Site | Dudley, United Kingdom, DY1 2HQ
    Investigators

      More Information

      Additional Relevant MeSH Terms

      • Hidradenitis Suppurativa
      • Hidradenitis
      • Sweat Gland Diseases
      • Skin Diseases
      • Skin Diseases, Bacterial
      • Bacterial Infections
      • Bacterial Infections and Mycoses
      • Infections
      • Skin Diseases, Infectious
      • Suppuration